Industry Daily Summary
Industry Daily Summary: What Happened on November 10, 2026
Boehringer pays $358 million for options on six Sino programs
Charles River will acquire Frontage’s Pennsylvania testing operations for about $470 million in cash.
Today in brief
Boehringer Ingelheim agreed to pay $358 million upfront for options on six preclinical Sino Biopharmaceutical programs, with up to $7 billion in potential milestones.1 Charles River agreed to acquire Frontage’s Pennsylvania testing business for about $470 million, plus up to $75 million tied to future performance.2
Boehringer takes options on six Sino programs
Boehringer Ingelheim agreed to pay Sino Biopharmaceutical $358 million upfront for options on six preclinical programs.1 The programs include antibody-drug conjugates and T cell engagers, and the agreement carries up to $7 billion in potential milestone payments.1 The companies reached the agreement on November 4.1
Charles River to buy Frontage’s Pennsylvania testing operations
Charles River signed definitive agreements to buy Frontage’s Pennsylvania bioanalysis and drug metabolism and pharmacokinetics operations for about $470 million in cash.2 The transaction could include up to $75 million in additional payments, depending on the business’s future financial performance.2
The acquisition covers two Exton sites totaling about 150,000 square feet, nearly 340 employees, and a central laboratory certified under the Clinical Laboratory Improvement Amendments.2 The facilities test biomarkers and support bioanalysis and drug metabolism and pharmacokinetics work for large and small molecules.2
The Pennsylvania operations generated about 40% of Frontage’s $256.7 million in 2025 revenue.2 Charles River is part of a consortium with Frontage’s controlling shareholder, Hongkong Tigermed, and chairman Song Li that plans to take Frontage private.2 After the planned privatization, Charles River is set to receive the Pennsylvania assets, while Tigermed and Li are to receive Frontage’s other operations.2
Charles River CEO Birgit Girshick said the acquisition supports the company’s bioanalysis strategy and responds to demand for scientific support as biologics and complex modalities grow.2 Charles River plans to fund the purchase with its credit facility and cash reserves, and to report the operations in its Discovery and Safety Assessment segment.2 The parties anticipate a closing sometime in the first six months of 2027, subject to regulatory clearances, shareholder approvals, and Cayman Islands court approval.2